Roots Analysis has done a detailed study on Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030.”, covering key aspects of the industry and identifying future growth opportunities.

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

Key Market Insights
 Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption
 Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements
 The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies
 Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities
 Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts
 Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies
 Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide
 Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies
 Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain
 As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

Table of Contents

TABLE OF CONTENTS

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Continuous Manufacturing
3.3. Continuous Manufacturing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of Continuous Manufacturing
3.3.3. Anticipated Shift to Continuous Manufacturing
3.3.4. Advantages of Continuous Manufacturing
3.3.5. Key Challenges Associated with Continuous Manufacturing
3.3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Companies with Expertise in Continuous Manufacturing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Manufacturing
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Location of Headquarters
4.2.6. Analysis by Location of Continuous Manufacturing Facilities
4.2.7. Analysis by Type of Drug Molecule
4.2.8. Analysis by Type of Continuous Manufacturing Related Service
4.2.9. Analysis by Type of Dosage Form
4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.11. Information on Production Capacity
4.2.12. Logo Landscape: Analysis by Year of Establishment and Company Size
4.2.13. Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form
4.2.14. Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

5. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES
5.1. Chapter Overview
5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview
5.2.2. Service Portfolio
5.2.3. Continuous Manufacturing Capabilities and Facilities
5.2.4. Recent Developments and Future Outlook

5.3. Cambrex
5.3.1. Company Overview
5.3.2. Service Portfolio
5.3.3. Continuous Manufacturing Capabilities and Facilities
5.3.4. Recent Developments and Future Outlook

5.4. Patheon
5.4.1. Company Overview
5.4.2. Service Portfolio
5.4.3. Continuous Manufacturing Capabilities and Facilities
5.4.4. Recent Developments and Future Outlook

5.5. SK biotek
5.5.1. Company Overview
5.5.2. Service Portfolio
5.5.3. Continuous Manufacturing Capabilities and Facilities
5.5.4. Recent Developments and Future Outlook

6. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES
6.1. Chapter Overview
6.2. Ajinomoto Bio-Pharma Services
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Continuous Manufacturing Capabilities and Facilities
6.2.4. Recent Developments and Future Outlook

6.3. Almac
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Continuous Manufacturing Capabilities and Facilities
6.3.4. Recent Developments and Future Outlook

6.4. Boehringer Ingelheim BioXcellence™
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Continuous Manufacturing Capabilities and Facilities
6.4.4. Recent Developments and Future Outlook

6.5. CordonPharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Continuous Manufacturing Capabilities and Facilities
6.5.4. Recent Developments and Future Outlook

6.6. Hovione
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Continuous Manufacturing Capabilities and Facilities
6.6.4. Recent Developments and Future Outlook

6.7. Lonza
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Continuous Manufacturing Capabilities and Facilities
6.7.4. Recent Developments and Future Outlook

7. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES
7.1. Chapter Overview
7.2. Kaneka
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Continuous Manufacturing Capabilities and Facilities
7.2.4. Recent Developments and Future Outlook

7.3. WuXi AppTec
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Continuous Manufacturing Capabilities and Facilities
7.3.4. Recent Developments and Future Outlook

8. RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Scale of Operation
8.3.4. Analysis by Type of Drug Molecule
8.3.5. Analysis by Type of Continuous Manufacturing Related Service
8.3.6. Analysis by Type of Dosage Form
8.3.7. Most Active Players: Analysis by Number of Partnerships

8.3.8. Regional Analysis
8.3.8.1. Intercontinental and Intracontinental Agreements

9. RECENT EXPANSIONS
9.1. Chapter Overview
9.2. Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Expanded Scale of Expansion
9.2.4. Analysis by Type of Drug Molecule
9.2.5. Analysis by Type of Continuous Manufacturing Related Service
9.2.6. Analysis by Type of Dosage Form
9.2.7. Most Active Players: Analysis by Number of Expansions

9.2.8. Regional Analysis
9.2.8.1. Analysis by Location of Expansion Project

10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Global, Continuous Manufacturing Capacity for Small Molecule APIs
10.3.1. Analysis by Company Size
10.3.2. Analysis by Purpose of Manufacturing
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Location of Headquarters
10.3.4. Analysis by Location of Continuous Manufacturing Facilities

10.4. Global, Continuous Manufacturing Capacity for Small Molecule End Products
10.4.1. Analysis by Company Size
10.4.2. Analysis by Purpose of Manufacturing
10.4.3. Analysis by Scale of Operation
10.4.4. Analysis by Location of Headquarters
10.4.5. Analysis by Location of Continuous Manufacturing Facilities

10.5. Global, Continuous Manufacturing Capacity for Biologic
10.5.1. Analysis by Company Size
10.5.2. Analysis by Purpose of Manufacturing
10.5.3. Analysis by Scale of Operation
10.5.4. Analysis by Location of Headquarters
10.5.5. Analysis by Location of Continuous Manufacturing Facilities

11. ACADEMIC GRANT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Continuous Manufacturing: List of Academic Grants
11.3.1. Analysis by Number of Grants
11.3.2. Analysis by Activity Code
11.3.3. Analysis by Grant Amount
11.3.4. Analysis by Focus Area
11.3.5. Analysis by Support Period
11.3.6 Popular Recipient Organizations: Analysis by Number of Grants
11.3.7 Analysis by Type of Recipient Organization
11.3.8. Analysis by Funding Institute Centre
11.3.9. Analysis by Funding Mechanism
11.3.10. Prominent Program Officers: Analysis by Number of Grants

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Continuous Manufacturing: Patent Analysis
12.3.1. Analysis by Publication Year
12.3.2. Analysis by Geography
12.3.3. Analysis by CPC Symbols
12.3.4. Emerging Focus Areas
12.3.5. Analysis by Type of Applicant
12.3.6. Leading Players: Analysis by Number of Patents
12.3.7. Continuous Manufacturing: Three-Dimensional Bubble Analysis
12.3.8. Continuous Manufacturing: Patent Valuation Analysis
12.3.8.1. Leading Patents: Information by Number of Citations

13. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES
13.1. Chapter Overview
13.2. Continuous Manufacturing Initiatives of Leading Companies
13.2.1. AbbVie
13.2.1.1. Partnered Initiatives
13.2.1.2 In-House Initiatives

13.2.2. Amgen
13.2.2.1. Partnered Initiatives
13.2.2.2. In-House Initiatives

13.2.3. Bristol-Myers Squibb
13.2.3.1. Partnered Initiatives
13.2.3.2. In-House Initiatives

13.2.4. GlaxoSmithKline
13.2.4.1. Partnered Initiatives
13.2.4.2. In-House Initiatives

13.2.5. Merck
13.2.5.1. Partnered Initiatives
13.2.5.2. In-House Initiatives

13.2.6. Novartis
13.2.6.1. Partnered Initiatives
13.2.6.2. In-House Initiatives

13.2.7. Pfizer
13.2.7.1. Partnered Initiatives
13.2.7.2. In-House Initiatives

13.2.8. Roche
13.2.8.1. Partnered Initiatives
13.2.8.2. In-House Initiatives
13.2.9. Sanofi
13.2.9.1. Partnered Initiatives
13.2.9.2. In-House Initiatives

14. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY
14.1. Chapter Overview
14.2. Historical Background
14.3. Concept of Modularization
14.3.1. Types of Modules
14.3.2. Modular Construction Process

14.4. Modular Construction in the Pharmaceutical Industry
14.4.1. Advantages of Modular Construction in the Pharmaceutical Industry

14.5. Modular Facility Manufacturers
14.5.1. Distribution by Industry Served
14.5.2. Distribution by Geography
14.5.3. Modular Projects Executed / Undertaken

14.6. Modular Pharmaceutical Cleanrooms
14.6.1. Cleanroom Classification and Current Standards
14.6.2. Advantages of Modular Cleanrooms
14.6.3. Regulations and Standards Concerning Modular Cleanroom Construction

14.7. Modular Cleanroom Providers
14.7.1. Distribution by Industry Served
14.7.2. Distribution by Geography
14.7.3. Type of Modular Cleanrooms Offered

15. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS
15.1. Chapter Overview
15.2. Types of Continuous Manufacturing Technologies
15.3. Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics
15.3.1. Continuous Blending and Mixing Equipment
15.3.2. Continuous Granulating Equipment
15.3.3. Continuous Drying Equipment
15.3.4. Continuous Compression Equipment
15.3.5. Continuous Coating Equipment
15.3.6. Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment
15.3.7. Continuous Chromatography Equipment
15.3.8. Continuous Reactors / Bioreactors
15.3.9. Full Line Continuous Platforms
15.3.10. Process Analytical Technologies
15.3.11. Other Technologies
15.4. Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

16. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES
16.1. Chapter Overview
16.2. Key Strategies for the Adoption of Continuous Manufacturing Processes
16.2. 1. Phase I: Process Development and Implementation
16.2. 2. Phase II: Equipment / Technology Development and Installation
16.2. 3. Phase III: Facility / Plant Development and Establishment
16.2. 4. Phase IV: Product Development and Manufacturing

17. MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Overall, Continuous Manufacturing Market, 2020-2030
17.3.1. Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030
17.3.2. Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030
17.3.3. Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030
17.3.4. Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030
17.3.5. Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030
17.3.6. Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

17.4. Continuous Manufacturing Market for Small Molecule, 2020-2030
17.4.1. Distribution by Purpose of Manufacturing, 2020-2030
17.4.2. Distribution by Scale of Operation, 2020-2030
17.4.3. Distribution by Type of Continuous Manufacturing Related Service, 2020-2030
17.4.4. Distribution by Key Geographical Regions, 2020-2030

17.5. Continuous Manufacturing Market for Biologic, 2020-2030
17.5.1. Distribution by Purpose of Manufacturing, 2020-2030
17.5.2. Distribution by Scale of Operation, 2020-2030
17.5.3. Distribution by Type of Continuous Manufacturing Related Service, 2020-2030
17.5.4. Distribution by Key Geographical Regions, 2020-2030

18. CONCLUSION
18.1. Chapter Overview
18.2. Key Takeaways

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Zaiput Flow Technologies
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

19.3. CONTINUUS Pharmaceuticals
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

19.4. Snapdragon Chemistry
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Eric Fang, Chief Scientific Officer

19.5. Enzene Biosciences
19.5.1. Company Snapshot
19.5.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

19.6. Pfizer
19.6.1. Company Snapshot
19.6.2. Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development
19.7. University of Strathclyde
19.7.1. Company Snapshot
19.7.2. Interview Transcript: Ian Houson, Technical Project Manager


20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]